CD19 and B-cell chronic lymphocytic leukemia: To interrogate the transcriptional changes associated with VIP152 treatment, we treated B-cells, isolated from four patients with treatment-naïve CLL, with 1 μM VIP152 or DMSO for two hours followed by fluorescence-assisted cell sorting for 500 live (Sytox−), CD45+/CD5+/CD19+ cells (Fig. 3A).